Analyst Price Target is $26.33
▲ +154.43% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for KalVista Pharmaceuticals in the last 3 months. The average price target is $26.33, with a high forecast of $35.00 and a low forecast of $20.00. The average price target represents a 154.43% upside from the last price of $10.35.
Current Consensus is
Buy
The current consensus among 3 polled investment analysts is to buy stock in KalVista Pharmaceuticals. This Buy consensus rating has held steady for over two years.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Read More
